Evidence map›Paper›PMID 41200208›Full record

ArticleCase reports in gastrointestinal medicine2025

Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum.

Ankit Mishra, Matthew Kubina, Dhiraj K Peddu, Benjamin L Viglianti, Anamarija M Perry, Priya Kathuria, Hellan Kwon, Shannon A Carty, Patricia Bloom

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in gastrointestinal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ankit MishraDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0002-7277-4027
Matthew KubinaDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Dhiraj K PedduDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.ORCID https://orcid.org/0000-0001-8366-9161
Benjamin L VigliantiDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, University of Michigan, Ann Arbor, Michigan, USA.
Anamarija M PerryDepartment of Pathology, University of Michigan, Ann Arbor, Michigan, USA.
Priya KathuriaDivision of Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, Michigan, USA.
Hellan KwonDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Shannon A CartyDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Patricia BloomDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a 64-year-old liver transplant recipient who developed early nondestructive post-transplant lymphoproliferative disorder (PTLD) and severe acute cellular rejection (ACR) concurrently. Hepatic lymphadenopathy led to a liver biopsy demonstrating early PTLD. Immunosuppression (IS) was reduced for early PTLD, which led to acute liver injury requiring high-dose steroids. However, subsequent augmentation in immunosuppression for ACR led to progression of PTLD, requiring rituximab treatment. This case highlights the complexity of managing conflicting liver transplant complications and underscores the importance of a multidisciplinary approach. In our case, prioritizing the treatment of rejection preserved the allograft function. Long-term follow-up showed complete resolution of both rejection and PTLD.

Identifiers

PMID41200208
PMCPMC12588761

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.